Awards for “PARTNER THERAPEUTICS, INC.”
11 awards on this page · sorted by amount · page 1
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| 75A50323F80027 | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $133.51M | 2023-09-26 | 2027-03-29 | 325412 | LEUKINE 250MCG VIL INJ (5PKG) |
| 75A50322F80018 | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $59.03M | 2022-07-25 | 2024-03-29 | 325412 | LEUKINE 250MCG/VIL INJ |
| 75A50119C00062 | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $55M | 2019-09-16 | 2020-09-15 | 325412 | LEUKINE 250MCG/VIL INJ 186,440 |
| HHSO10033003T | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $37.63M | 2016-09-30 | 2021-09-29 | 325414 | IGF::OT::IGF FOR OTHER FUNCTIONS PROJECT: ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION (RTOR-CSF-0003) |
| HHSO10033002T | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $13.94M | 2013-09-30 | 2018-09-29 | 325414 | IGF::OT::IGF TASK ORDER 2 UNDER RFP-12-100-SOL-00016 |
| 75A50124C00061 | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $12.99M | 2024-09-30 | 2028-03-31 | 541715 | PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS |
| 75A50121C00080 | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $748.91K | 2021-09-02 | 2023-07-31 | 541714 | PARTNER THERAPEUTICS, INC.: .: BARDA DRIVE : RESEARCH AND DEVELOPMENT OF DIAGNOSTIC TESTS FOR PATIENTS WITH SEPSIS AND IMMUNOPARALYSIS |
| 75A50123C00064 | PARTNER THERAPEUTICS, INC. | Department of Health and Human Services | $748.04K | 2023-09-25 | 2026-01-30 | 541714 | R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT |
| 36C24626N0782 | PARTNER THERAPEUTICS, INC. | Department of Veterans Affairs | $72.56K | 2026-06-16 | 2026-07-10 | 325412 | EMERG. BIZENGRI MEDS FOR VETERAN |
| 36C24626N0690 | PARTNER THERAPEUTICS, INC. | Department of Veterans Affairs | $54.42K | 2026-05-05 | 2026-05-19 | 325412 | EMERGENCY BIZENGRI MEDS. FOR VETERAN |
| 36C24626N0637 | PARTNER THERAPEUTICS, INC. | Department of Veterans Affairs | $36.28K | 2026-04-10 | 2026-04-24 | 325412 | EMERGENCY BIZENGRI MEDS FOR VETERAN |